The financial burden of destination left ventricular assist device therapy: Who and when?

Current Cardiology Reports

Volumn 9, Issue 3, 2007, Pages 194-199

  Bieniarz, Mark C ^b   Delgado, Reynolds ^a  

^a TEXAS HEART INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT;

CARDIOPULMONARY BYPASS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLON CANCER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; EQUIPMENT DESIGN; FEASIBILITY STUDY; HEALTH CARE NEED; HEALTH ECONOMICS; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART FAILURE; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; INVASIVE PROCEDURE; KIDNEY FAILURE; MORTALITY; PATIENT SELECTION; POSTOPERATIVE CARE; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SODIUM RESTRICTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ANIMALS; HEALTH CARE COSTS; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HUMANS; TREATMENT OUTCOME;

EID: 34249087410     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938350     Document Type: Review

References (19)

1. Ho KK, Pinsky JL: The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993, 22:S6A-S13A.
2. Levy D, Kenchaiah S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
3. Redfield MM: Heart failure - an epidemic of uncertain proportions. N Engl J Med 2002, 347:1442-1444.
4. Blue Cross Blue Shield Association Medical Advisory Panel. Special report: cost effectiveness of left ventricular assist devices as destination therapy for end stage heart failure. Blue Cross Blue Shield Technology Evaluation Center Bulletin 2004, 19:1-29.
5. Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
6. Centers for Medicare and Medicaid Services. Medicare Coverage Database. Available at http://www.cms.hhs.gov/mcd/ viewncd.asp?ncd_id=20.9&ncd_version= 2&basket=ncd%3A20%2E9%3A2%3AArtificial+Hearts+and+Related+Devices. Accessed February 14, 2007.
7. Miller L, Lietz K: Candidate selection for long-term ventricular assist device therapy for refractory heart failure. J Heart Lung Transplant 2006, 25:756-764.
8. Stevenson LW, Miller LW, Desvigne-Nickens P, et al.: Left ventricular assist device as destination therapy for patients undergoing intravenous inotrope therapy. Circulation 2004, 110:975-981.
9. Birks EJ, Tansley PD, Hardy J, et al.: Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355:1873-1884.
10. Oz MC, Gelijns AC, Miller L, et al.: Left ventricular assist devices as permanent heart failure therapy- the price of progress. Ann Surg 2003, 238:577-585.
11. Miller LW, Nelson KE, Bostic RR, et al.: Hospital costs for left ventricular assist device for destination therapy: lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant 2006, 25:778-784.
12. de Lissovoy G: Medicare and heart transplants: will lightning strike twice? Health Aff 1988, 7:61-72.
13. Moskowitz AJ, Rose EA, Gelijns AC: The cost of long-term LVAD implantation. Ann Thorac Surg 2001, 71:S195-S198.
14. Schrag D: The price tag on progress. N Engl J Med 2004, 351:317-319.
15. Carrier M: Left ventricular assist device: can Canada afford this? Can J Cardiol 2005, 21:1166-1168.
16. Mussivand T: Medicare reimbursement for destination therapy: the right decision at the right time? Artif Organs 2004, 28:523-525.
17. Van Nooten G: Medicare reimbursement for destination therapy. Artif Organs 2004, 28:526-528.
18. Beyersdorf F: Economics of ventricular assist devices: European view. Ann Thorac Surg 2001, 71:S192-S194; discussion S202-S203.
19. Portner P: Economics of devices. Ann Thorac Surg 2001, 71:S199-S201; discussion 203-204.